Eli Lilly’s new Prozac Fact Sheet (image below) sent to UK physicians–but not to US physicians–states that Prozac is NOT RECOMMENDED FOR CHILDREN for any indication. For a larger view, please click on the image.
Lilly Consultants dismiss significance of suicide risk while Lilly will issue Black Box warning label for Strattera Mon, 10 Oct 2005 On September 29, the FDA issued the public health advisory alerting health care professionals that children and adolescents taking Strattera prescribed for ADHD should be closely monitored for changes…
AHRP Comments Re: EPA Proposed Rule for Human Pesticide Research Wed, 30 Nov 2005 Help us stop a proposed government policy that would lead to the proliferation of unthinkable human pesticide experiments such as the infamous CHEERS experiment. CHEERS was designed to expose toddlers to pesticides so that EPA investigators…
Death & Other Problems at Fargo VA Research Detroit_BNA Mon, 21 Apr 2003 Medical research at the Department of Veterans Affairs appears to be in disarray–veterans’ lives are at serious risk in an environment that does not take seriously federal safety requirements. It is apparent that during its tenure as…
John H. Noble, Jr., Ph.D. John H. Noble, Jr., Ph.D., retired in August, 2005, from his position as Endowed Professor for Social Justice, The Catholic University of America. He has been Professor Emeritus since 1993 at the State University of New York at Buffalo, where he held joint appointments in…
Why We Need Whistleblowers–One-third US Scientists Admit Unethical Research Practices Sat, 11 Jun 2005 Although the major focus of these AHRP Infomails has been on the deplorable misconduct by the pharmaceutical industry and government health care agencies, whenever we pointed a flashlight at academia and biomedical scientists, we raised the…
Cong Hearing Re: Disclosure Pediatric SSRI Trials Wed, 7 Jul 2004 A hearing has been tentatively set for July 20th by the House subcommittee on oversight and investigations, chaired by Congressman James Greenwood. The hearing will address issues of disclosure involving pediatric antidepressant drug trials–or more accurately, non-disclosure of adverse…
